Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile
- Conditions
- C. Difficile
- Registration Number
- NCT05389904
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
Clostridioides difficile (C. difficile) is the most common healthcare-associated pathogen, causing \>500,000 infections and \>29,000 deaths per year in the US. Traditional approaches to reduce hospital-onset CDI focus on identifying, isolating, and treating symptomatic patients to prevent transmission to other patients. Recent genomic epidemiology studies, however, suggest that most hospital-onset CDI cases are attributable to asymptomatic carriers who either progress from colonization to active infection themselves or transmit C. difficile to other patients while asymptomatic. This trial will evaluate an intervention to pre-emptively identify asymptomatic C. difficile carriers and then implement a patient-tailored prevention package to protect the carrier from progression to active infection and to prevent transmission from the carrier to other patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
- Patients admitted to ICU or Oncology units and identified to carry C. Difficile via VRE swab
- Patients not identified as carriers of C. difficile and patients not admitted to ICU or oncology units
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Risk of C. difficile infection among patients colonized with C. difficile comparing the intervention to the control group 24 months Incidence rate ratio of CDI in colonized patients who received the intervention bundle versus who did not receive the intervention bundle
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States